# A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

> **NCT06855823** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 33 (estimated)

## Conditions studied

- Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

## Interventions

- **DRUG:** Golicitinib combined with Pomadomide

## Key facts

- **NCT ID:** NCT06855823
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-14
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06855823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06855823, "A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06855823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*